Transcription Factors and Methods for the Pharmacological Correction of Their Activity

Svetlana V Guryanova1,2, Tatiana V Maksimova2, Madina M Azova2

  • 1M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.

Insights

Transcription factors (TFs) are crucial for gene expression and cell function. New strategies are emerging to target TFs for treating diseases like cancer, despite challenges in drug development.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Genetics

Background:

  • Transcription factors (TFs) regulate gene expression and are vital for cellular processes.
  • Dysregulated TFs are linked to diseases such as cancer, autoimmune disorders, and neurodegeneration.
  • Historically considered undruggable, TFs are now targets for novel therapeutic interventions.

Purpose of the Study:

  • To review current pharmacological strategies for modulating transcription factor activity.
  • To highlight key transcription factor families and their roles in disease.
  • To discuss challenges and future directions in TF-targeted therapies.

Main Methods:

  • Review of existing literature on transcription factor biology and pharmacology.
  • Analysis of major transcription factor families (NF-κB, p53, STATs, HIF-1α, AP-1, Nrf2) and their therapeutic targeting.
  • Categorization of pharmacological strategies, including inhibitors, activators, PROTACs, and epigenetic modulators.

Main Results:

  • Several TF families (NF-κB, p53, STATs, HIF-1α, AP-1, Nrf2) are implicated in various diseases and have specific inhibitors or activators.
  • Diverse pharmacological approaches are being developed, including small molecule inhibitors, activators, PROTACs, molecular glues, and epigenetic modifiers.
  • Examples of targeted TFs and their associated drugs include NF-κB inhibitors, p53 reactivators (Nutlin-3, APR-246), HIF-1α inhibitors/stabilizers (acriflavine, roxadustat), STAT inhibitors (JAK inhibitors, SD-36), AP-1 inhibitors (T-5224), and Nrf2 modulators.

Conclusions:

  • Transcription factor modulation represents a promising therapeutic avenue for numerous diseases.
  • Overcoming challenges like structural inaccessibility, off-target effects, and delivery is crucial for clinical success.
  • Continued research focusing on specificity, safety, and efficient delivery will unlock the full potential of TF-targeted therapies.

Related Concept Videos

Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
77.0K
General Transcription Factors01:30

General Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
5.6K
Combinatorial Gene Control02:33

Combinatorial Gene Control

Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
8.4K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.0K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.6K
Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.9K